Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemia

Thrombosis and Haemostasis

Volumn 110, Issue 1, 2013, Pages 153-161

  Sun, Li ^a   Zhou, Wei ^a   Ploen, Robert ^a   Zorn, Markus ^a   Veltkamp, Roland ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cerebral ischaemia; Haemorrhage; Oral anticoagulation; Thrombolysis

Indexed keywords

ALTEPLASE; BLOOD CLOTTING FACTOR; DABIGATRAN ETEXILATE; GELATIN; GELATINASE B; RECOMBINANT THROMBOPLASTIN; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BLOOD BRAIN BARRIER; BLOOD CLOT LYSIS; BLOOD CLOTTING TIME; BRAIN BLOOD VOLUME; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG MEGADOSE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION; SPECTROFLUOROMETRY; SPECTROPHOTOMETRY; THROMBOEMBOLISM; ZYMOGRAPHY;

ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD-BRAIN BARRIER; CEREBRAL ARTERIES; CEREBRAL HEMORRHAGE; DISEASE MODELS, ANIMAL; HUMANS; ISCHEMIA; MICE; MICE, INBRED C57BL; RATS; STROKE; THROMBOLYTIC THERAPY; WARFARIN;

EID: 84879621987     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-12-0942     Document Type: Article

References (38)

1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
2. Waldo AL, Becker RC, Tapson VF, et al. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol 2005; 46: 1729-1736.
3. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010; 115: 15-20.
4. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
5. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
6. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
7. Steiner T, Petersson J, Al-Shahi Salman R, et al. European research priorities for intracerebral haemorrhage. Cerebrovasc Dis 2011; 32: 409-419.
8. Watanabe M, Siddiqui FM, Qureshi AI. Incidence and management of ischaemic stroke and intracerebral haemorrhage in patients on dabigatran etexilate treatment. Neurocrit Care 2012; 16: 203-209.
9. Adams HP, Jr., del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischaemic stroke: A guideline from the american heart association/ american stroke association stroke council, clinical cardiology council, cardiovascular radiology and intervention council, and the atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups: The american academy of neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 2007; 115: e478-534.
10. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischaemic stroke. N Engl J Med 2008; 359: 1317-1329.
11. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: An updated pooled analysis of ecass, atlantis, ninds, and epithet trials. Lancet 2010; 375: 1695-1703.
12. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (sits-most): An observational study. Lancet 2007; 369: 275-282.
13. Prabhakaran S, Rivolta J, Vieira JR, et al. Symptomatic intracerebral haemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischaemic stroke. Arch Neurol 2010; 67: 559-563.
14. Pfeilschifter W, Spitzer D, Pfeilschifter J, Steinmetz H, Foerch C. Warfarin anticoagulation exacerbates the risk of haemorrhagic transformation after rt-pa treatment in experimental stroke: Therapeutic potential of pcc. PLoS One 2011; 6: e26087.
15. Sun L, Zhou W, Ploen R, et al. Rapid reversal of anticoagulation prevents excessive secondary haemorrhage after thrombolysis in a thromboembolic model in rats. Stroke 2011; 42: 3524-3529.
16. Illanes S, Zhou W, Schwarting S, et al. Comparative effectiveness of haemostatic therapy in experimental warfarin-associated intracerebral haemorrhage. Stroke 2011; 42: 191-195.
17. Zhou W, Schwarting S, Illanes S, et al. Haemostatic therapy in experimental intracerebral haemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594-3599.
18. Longa EZ, Weinstein PR, Carlson S, et al. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989; 20: 84-91.
19. Sun L, Marti HH, Veltkamp R. Hyperbaric oxygen reduces tissue hypoxia and hypoxia-inducible factor-1 alpha expression in focal cerebral ischaemia. Stroke 2008; 39: 1000-1006.
20. Toomey JR, Valocik RE, Koster PF, et al. Inhibition of factor ix(a) is protective in a rat model of thromboembolic stroke. Stroke 2002; 33: 578-585.
21. Sun L, Zhou W, Heiland S, et al. A translationally relevant thromboembolic stroke model for the study of secondary haemorrhage after thrombolysis in rats. Brain Res 2011; 1368: 346-354.
22. Sun L, Zhou W, Mueller C, et al. Oxygen therapy reduces secondary haemorrhage after thrombolysis in thromboembolic cerebral ischaemia. J Cereb Blood Flow Metab 2010; 30: 1651-1660.
23. Pfeilschifter W, Bohmann F, Baumgarten P, et al. Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke. Ann Neurol 2012; 71: 624-633.
24. Illanes S, Zhou W, Heiland S, et al. Kinetics of hematoma expansion in murine warfarin-associated intracerebral haemorrhage. Brain Res 2010; 1320: 135-142.
25. Bederson JB, Pitts LH, Tsuji M, et al. Rat middle cerebral artery occlusion: Evaluation of the model and development of a neurologic examination. Stroke 1986; 17: 472-476.
26. Swanson RA, Morton MT, Tsao-Wu G, et al. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 1990; 10: 290-293.
27. Choudhri TF, Hoh BL, Solomon RA, et al. Use of a spectrophotometric haemoglobin assay to objectively quantify intracerebral haemorrhage in mice. Stroke 1997; 28: 2296-2302.
28. Wang X, Lee SR, Arai K, et al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 2003; 10: 1038.
29. Bohmann F, Mirceska A, Pfeilschifter J, et al. No influence of dabigatran anticoagulation on haemorrhagic transformation in an experimental model of ischaemic stroke. PLoS One 2012; 7: e40804.
30. Lauer A, Cianchetti FA, Van Cott EM, et al. Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral haemorrhage. Circulation 2011; 124: 1654-1662.
31. De Smedt A, De Raedt S, Nieboer K, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis 2010; 30: 533-534.
32. Matute MC, Guillán M, García-Caldentey J, et al. Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran. Thromb Haemost 2011; 106: 178-179.
33. Casado Naranjo I, Portilla-Cuenca JC, Jiménez Caballero PE, et al. Fatal intracerebral haemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran. Cerebrovasc Dis 2011; 32: 614-615.
34. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial haemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004; 141: 745-752.
35. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The stroke prevention in atrial fibrillation investigators. Arch Intern Med 1996; 156: 409-416.
36. Rosand J, Eckman MH, Knudsen KA, et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral haemorrhage. Arch Intern Med 2004; 164: 880-884.
37. Steiner T, Rosand J, Diringer M. Intracerebral haemorrhage associated with oral anticoagulant therapy: Current practices and unresolved questions. Stroke 2006; 37: 256-262.
38. Cheng T, Petraglia AL, Li Z, et al. Activated protein C inhibits tissue plasminogen activator-induced brain haemorrhage. Nat Med 2006; 12: 1278-1285.